179 related items for PubMed ID: 19888533
1. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
Agledahl I, Brodin E, Svartberg J, Hansen JB.
Thromb Haemost; 2009 Nov; 102(5):945-50. PubMed ID: 19888533
[Abstract] [Full Text] [Related]
2. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
Agledahl I, Brodin E, Svartberg J, Hansen JB.
Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
[Abstract] [Full Text] [Related]
3. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G.
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[Abstract] [Full Text] [Related]
4. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
[Abstract] [Full Text] [Related]
5. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
Kojima T, Gando S, Kemmotsu O, Mashio H, Goda Y, Kawahigashi H, Watanabe N.
J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
[Abstract] [Full Text] [Related]
6. Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
Bartok A, Steiner S, Seidinger D, Jetzl A, Huber K, Minar E, Stefenelli T, Kopp CW.
Thromb Res; 2005 Feb; 115(6):469-74. PubMed ID: 15792677
[Abstract] [Full Text] [Related]
7. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
Xiong SL, Wang Q, Zheng L, Li JL, Wen ZB, He SL.
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
[Abstract] [Full Text] [Related]
8. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
Adams M, Breckler L, Stevens P, Thom J, Baker R, Oostryck R.
Haematologica; 2004 Aug; 89(8):985-90. PubMed ID: 15339683
[Abstract] [Full Text] [Related]
9. Regulation of thrombin generation by TFPI in plasma without and with heparin.
Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, Hansen JB.
Transl Res; 2009 Mar; 153(3):124-31. PubMed ID: 19218095
[Abstract] [Full Text] [Related]
10. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
Peverill RE, Teede HJ, Smolich JJ, Malan E, Kotsopoulos D, Tipping PG, McGrath BP.
Clin Sci (Lond); 2001 Jul; 101(1):93-9. PubMed ID: 11410120
[Abstract] [Full Text] [Related]
11. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
Lean SY, Ellery P, Ivey L, Thom J, Oostryck R, Leahy M, Baker R, Adams M.
Haematologica; 2006 Oct; 91(10):1360-6. PubMed ID: 17018385
[Abstract] [Full Text] [Related]
12. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease.
Berrettini M, Parise P, Ricotta S, Iorio A, Peirone C, Nenci GG.
Thromb Haemost; 1996 Mar; 75(3):395-400. PubMed ID: 8701396
[Abstract] [Full Text] [Related]
13. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Lizakowski S, Zdrojewski Z, Jagodzinski P, Rutkowski B.
Scand J Urol Nephrol; 2007 Mar; 41(3):237-42. PubMed ID: 17469034
[Abstract] [Full Text] [Related]
14. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R.
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[Abstract] [Full Text] [Related]
15. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Lupu C, Kruithof EK, Kakkar VV, Lupu F.
Thromb Haemost; 1999 Dec; 82(6):1652-8. PubMed ID: 10613651
[Abstract] [Full Text] [Related]
16. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG.
Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
[Abstract] [Full Text] [Related]
17. The effects of pharmacologically induced hypogonadism on mood in healthy men.
Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, Rubinow DR.
Arch Gen Psychiatry; 2004 Oct; 61(10):997-1004. PubMed ID: 15466673
[Abstract] [Full Text] [Related]
18. Thrombin generation in vitro and in vivo, and disturbed tissue factor regulation in patients with acute pancreatitis.
Lindström OK, Tukiainen EM, Kylänpää ML, Mentula PJ, Puolakkainen PA, Wartiovaara-Kautto UM, Repo H, Petäjä JM.
Pancreatology; 2011 Oct; 11(6):557-66. PubMed ID: 22213026
[Abstract] [Full Text] [Related]
19. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Dougherty RH, Rohrer JL, Hayden D, Rubin SD, Leder BZ.
Clin Endocrinol (Oxf); 2005 Feb; 62(2):228-35. PubMed ID: 15670201
[Abstract] [Full Text] [Related]
20. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
Naumnik B, Borawski J, Chyczewski L, Pawlak K, Mysliwiec M.
Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
